Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

CRM Giant Salesforce Reducing Workforce & Cutting Infrastructural Costs – $CRM $DIA $INVO

By John F. Heerdink, Jr.

Reportedly, Salesforce (CRM) is reducing its office space footprint and cut 10% of its employees as part of a restructuring plan amid slow revenue growth expected in fiscal 2024. The company expects to incur about $1.4 billion to $2.1 billion in charges from the plan, and up to $1 billion of the charges will impact the current January quarter.  The CRM giant had nearly 80,000 global employees as of October 31 and expects employee layoffs to be majorly complete by the end of fiscal 2024 with real estate reductions getting completed in fiscal 2026.

The restructuring plan is “intended to reduce operating costs, improve operating margins, and continue advancing the company’s ongoing commitment to profitable growth,” stated Salesforce.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also provides select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.


Fertility rates have hit a record low in the United States. The latest US government fertility statistics come from 2019, and they estimate there were 58.2 births year per 1,000 women of childbearing age (defined by the CDC as women between ages 15 and 44).

If you have ever struggled with infertility issues, or know someone who has, you are probably well aware of how demoralizing it can be. Imagine for a moment spending thousands of dollars and months of intensive medical procedure only to end up empty handed, exhausted, sad, and defeated because after all of that time, work, and money, you still don’t have a baby. That’s an incredibly difficult situation, and it’s becoming more common each passing year. Likewise, the need for more effective, less invasive infertility treatment options is increasing with each passing year. This is the sole focus of medtech company INVO Bioscience (NASDAQ: INVO). Learn more by reading the following story that we published recently. 

INVO Bioscience (NASDAQ: $INVO), A Company Seeking To Address A Massively Underserved Fertility Market

(Read Original Story: Salesforce To Cut 10% Of Workforce Amid Tech Sector Slowdown in Investor's Business Daily)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us